Balchem Agrees to Acquire Kappa Bioscience

Balchem Corporation (New Hampton, NY), a global specialty ingredients company focused on nutrition and health, has signed a definitive agreement to acquire Kappa Bioscience AS, a manufacturer of specialty vitamin K2 for the human nutrition industry, headquartered in Oslo, Norway.

Vitamin K2 is a fast-growing specialty vitamin that plays a crucial role in the human body for bone health, heart health, immunity and athletic performance. Primarily, vitamin K2 supports the transport and distribution of calcium in the body. Vitamin K2 is important at all life stages, from pregnancy and early life to healthy aging. Kappa’s K2VITAL branded vitamin K2 is the leading synthetic vitamin K2 and is backed by intellectual property and a clinical research portfolio, according to the company.

“We are thrilled to welcome Kappa Bioscience’s strong and experienced team to Balchem,” said Ted Harris, chairman, CEO and president of Balchem. “This acquisition accelerates our strategy to expand our portfolio of science-based specialty nutrients with leading positions in growing markets. Vitamin K2 fits squarely with our strategic focus and our vision of ‘making the world a healthier place’. Kappa is the leader within its space and the only company offering a patented, 99.7 percent all-trans vitamin K2 as MK-7, identical to the bioactive vitamin K2 molecule found in nature. We believe the combining of our two companies will strengthen our scientific and technical expertise, geographic reach, and marketplace leadership while ultimately leading to accelerated growth for both companies’ portfolios.”

“We are extremely excited to join Balchem, a market leader in human nutrition and health and a science-driven company that aligns well with our vision to improve the quality of life for all,” added Egil Greve, Kappa Bioscience president & CEO. “Our partners can expect continued expert knowledge, scientific excellence, product safety and quality, and customer service as we further strengthen these areas together with Balchem”

Balchem is acquiring Kappa from majority owner Verdane Edda for an enterprise value of NOK 3.175B (approximately $338M [U.S.]). Following the acquisition, Kappa will be included in Balchem’s Human Nutrition and Health business segment.

For more information, visit https://balchem.com.